Table 3 Treatment-related characteristics of study participants in heart failure patients with at selected South Wollo general Hospitals, Ethiopia, 2022
Variables | Category | Status | Total (%) (n = 572) | |
|---|---|---|---|---|
Readmitted (%) (n= 151) | No- Readmitted (%) (n = 421) | |||
Digoxin | No | 89(58.94) | 399(94.77) | 488(85.31) |
Yes | 62(41.06) | 22(5.23) | 84(14.69) | |
Diuretics | No | 19(12.58) | 165(39.19) | 184(32.17) |
Yes | 132(87.42) | 256(60.81) | 388(67.83) | |
ACEI | No | 73 (48.34) | 134(31.83) | 207(36.19) |
Yes | 78(51.66) | 287(68.17) | 365(63.81) | |
ARB | No | 100(66.23) | 285(67.70) | 385(67.31) |
Yes | 51(33.78) | 136(32.30) | 187(32.69) | |
BB | No | 98(64.90) | 121(28.74) | 219(38.29) |
Yes | 53(35.10) | 300(71.26) | 353(61.71) | |
Vasodilators | No | 134(88.74) | 383(90.98) | 517(90.38) |
Yes | 17(11.26) | 38(9.03) | 55(9.62) | |
Anti-platelet | No | 74(49.01) | 241(57.25) | 315(55.07) |
Yes | 77(50.99) | 180(42.76) | 257(44.93) | |
Statin | No | 141(93.38) | 379(90.02) | 520(90.91) |
Yes | 10(6.62) | 42(9.98) | 52(9.09) | |